Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Many children with epilepsy experience seizures which respond well to treatment. A few types of epilepsy, however, are characterized by seizures which begin very early in childhood and are associated with severe intellectual and/or developmental disabilities. These conditions, known as progressive epileptic encephalopathies, are particularly severe and are often difficult to treat. These syndromes include infantile spasms, early infantile epileptic encephalopathy with suppression bursts (Ohtahara syndrome), malignant migrating partial epilepsy of infancy, early myoclonic epileptic encephalopathy, and severe myoclonic epilepsy of infancy (Dravet syndrome).
Our current research efforts are focused on children with early onset epilepsies with no know genetic cause. Our goal is to identify genetic alterations (known as “mutations”) that cause epilepsy with the hopes of improving diagnosis and treatment for these. It is also possible that understanding the genetic basis of early-onset epilepsies may in some instances make it possible to prevent it from occurring in the future.
If your child has been diagnosed with an early onset epilepsy syndrome, your family may be eligible to participate in Boston Children Hospital’s Genetics of Epilepsy and Related Neurological Disorders research protocol. Your family does not need to live in the Boston area to participate. Eligibility includes children with the following diagnoses:
Participation in this research study includes providing a blood sample (or another source of DNA, such as saliva). We also collect blood/DNA samples from both biological parents and in some instances siblings. In addition, we will conduct a detailed interview (either by phone or in person) to collect family and medical history. This interview will last approximately 1 hour. We will also review your child’s medical records, including EEG data and any imaging studies (such as MRI) performed in the past, in order to get a complete overview of your child’s medical history.
No, there is no cost to participate in this research study and we do not provide any financial compensation. You will be reimbursed for any expenses related to the study.
Through our research, we hope to identify gene mutations that help explain early onset epilepsy. In order to do this, we need DNA samples from many children with the same or similar diagnosis, as well as from their immediate family members. Rather than looking at specific genes already known to play a role in epilepsy, we are performing exome sequencing, a technique which enables us to examine all 20,000 genes in the entire human genome. You will have the opportunity to decide if you would like to be notified of research results when they become available. If we identify genetic information that is relevant to your child’s epilepsy diagnosis, we will notify you and you will have the opportunity to learn the results. It is important to note, however, that research takes considerable time and it may be months or even years before we have any information that could be clinically useful to individuals or families.
If you would like to participate in The Genetics of Epilepsy and Related Disorders study, or if you have questions about research, you can reach the Epilepsy Genetics Program by email at:
EpilepsyGenetics@Childrens.Harvard.edu or please call 617-355-5254
We look forward to hearing from you!
PCDH19-Related Epilepsy is a rare genetic type of epilepsy characterized by difficult to treat seizures as well as developmental and behavioral issues. It is caused by DNA sequence changes (“mutations”) in the PCDH19 gene and typically affects females only. Males who have mutations in the PCDH19 gene are often spared from these features. Currently, little is known about PCDH19-Related Epilepsy, and there are no targeted treatments available.
A registry gathers and keeps information about people with a certain condition to support and encourage research into that condition. The purpose of the PCDH19-Related Epilepsy Registry is to maintain a database of information from individuals with PCDH19-Related Epilepsy and their family members that can be accessed for future research to gain a better understanding of PCDH19-Related Epilepsy and ultimately develop more effective treatment options. For example:
Any individual with a reported PCDH19 gene mutation or variant is eligible to participate. This includes individuals affected by PCDH19-Related Epilepsy and any family member who has been tested and found to carry the PCDH19 gene mutation or variant (regardless of whether or not they have any symptoms).
Participation in this study involves completing a medical and family history questionnaire at the time of enrollment, as well as additional questionnaires regarding any updates to the medical and family history at designated time intervals. We will also ask permission to obtain a copy of the participant’s medical record. We may also contact the participant’s family in the future if the participant is eligible to contribute to other research studies that aim to advance the knowledge of PCDH19-Related Epilepsy.
There is no cost to participate in this study, and there will be no financial compensation for your/your child’s participation in this study.
If you would like more information on, or are interested in enrolling in the PCDH19-Related Epilepsy Registry, you may contact Lacey Smith, MS, at:
PCDH19registry@childrens.harvard.edu or please call 857-218-3239
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”